Share Price and Basic Stock Data
Last Updated: November 22, 2025, 2:57 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gayatri BioOrganics Ltd operates in the chemicals sector, specifically focusing on organic cellulose derivatives. The company’s stock price stood at ₹12.00 with a market capitalization of ₹94.6 Cr. Despite its foundational role in the chemicals industry, Gayatri BioOrganics has faced significant challenges reflected in its revenue performance. The company reported sales of ₹1.67 Cr for the fiscal year ending March 2023, after a prolonged period of zero sales from March 2020 to March 2022. This minimal revenue generation highlights severe operational challenges. The absence of sales in subsequent quarters through June 2024 indicates ongoing difficulties in scaling operations. The historical sales peaked at ₹255.89 Cr in March 2015, showcasing a stark contrast to the current figures, which raises concerns about the company’s ability to regain its previous market position.
Profitability and Efficiency Metrics
In terms of profitability, Gayatri BioOrganics has consistently reported losses over multiple fiscal periods. The company recorded a net profit of -₹1.01 Cr in March 2023, declining further to -₹0.68 Cr in March 2024 and -₹0.73 Cr in March 2025. The operating profit margin (OPM) for March 2023 was reported at -46.11%, indicating inefficiencies in managing operational costs relative to revenues. The interest coverage ratio was -1.62 in March 2025, underlining the company’s struggles to meet interest obligations on its debt. The return on capital employed (ROCE) also remained negative at -54.61% in March 2023, reflecting poor utilization of capital. Such metrics suggest that Gayatri BioOrganics is grappling with operational inefficiencies, which are critical for potential recovery and growth.
Balance Sheet Strength and Financial Ratios
Analyzing the balance sheet, Gayatri BioOrganics displays a concerning financial structure. The company has no reported reserves or borrowings, which could suggest a lack of financial leverage or investment in growth opportunities. However, the negative book value per share of ₹-4.55 as of March 2025 indicates that liabilities exceed assets, raising red flags for potential investors. The current ratio stood at 0.04, which is significantly below the typical threshold of 1, indicating liquidity issues that could hinder operational continuity. Furthermore, the price-to-book value ratio of -1.50x suggests that the market is valuing the company’s equity at a significant discount, reflecting negative investor sentiment. These factors collectively highlight the financial fragility of Gayatri BioOrganics and the need for strategic interventions.
Shareholding Pattern and Investor Confidence
The shareholding pattern reveals a significant shift in ownership dynamics over recent periods. As of March 2025, promoters held 21.59% of the company, a marked decline from 40.63% in the previous year. This reduction in promoter stake may raise concerns regarding their confidence in the company’s future. Conversely, public shareholding increased to 77.77%, indicating growing retail investor interest, albeit amidst a backdrop of poor performance. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), held minimal stakes of 0.01% and 0.65%, respectively, reflecting limited institutional confidence in Gayatri BioOrganics. The overall increase in public shareholders to 32,123 suggests an opportunity for the company to potentially engage more with retail investors but also highlights the need for improved communication regarding its strategic direction.
Outlook, Risks, and Final Insight
The outlook for Gayatri BioOrganics is contingent on its ability to restore operational performance and profitability. The company faces several risks, including ongoing operational inefficiencies, a negative equity position, and a lack of institutional support, which could impede its recovery. Additionally, the absence of significant sales in recent quarters raises concerns about market demand for its products. On the other hand, the increase in public shareholders presents a potential avenue for raising capital, provided the company can effectively communicate its turnaround strategy. Should Gayatri BioOrganics manage to stabilize its operations and regain market confidence, it could attract further investment. However, without substantial changes, the risk of continued financial distress remains high, necessitating immediate and strategic management interventions to reverse the current trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Gayatri BioOrganics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gayatri BioOrganics Ltd | 93.3 Cr. | 11.8 | 13.8/5.35 | 4.62 | 0.00 % | 40.7 % | % | 10.0 | |
| Industry Average | 0 Cr | 11.80 | 0 | 4.62 | 0.00% | 40.70% | 0% | 10.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 1.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.16 | 0.24 | 0.12 | 2.31 | 0.18 | 0.07 | 0.10 | 0.18 | 0.15 | 0.11 | 0.08 | 0.10 | 0.18 |
| Operating Profit | -0.16 | -0.24 | -0.12 | -0.64 | -0.18 | -0.07 | -0.10 | -0.18 | -0.15 | -0.11 | -0.08 | -0.10 | -0.18 |
| OPM % | -38.32% | ||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | 0.04 | 0.04 | 0.05 | 0.06 | 0.07 | 0.08 | 0.07 | 0.08 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.16 | -0.24 | -0.12 | -0.67 | -0.20 | -0.11 | -0.14 | -0.23 | -0.21 | -0.18 | -0.16 | -0.17 | -0.26 |
| Tax % | 0.00% | 87.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.16 | -0.45 | -0.12 | -0.67 | -0.20 | -0.11 | -0.14 | -0.23 | -0.21 | -0.18 | -0.16 | -0.17 | -0.26 |
| EPS in Rs | -0.02 | -0.06 | -0.02 | -0.09 | -0.03 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 | -0.03 |
Last Updated: August 19, 2025, 2:50 pm
Below is a detailed analysis of the quarterly data for Gayatri BioOrganics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Jun 2025, the value is 0.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.10 Cr. (Mar 2025) to 0.18 Cr., marking an increase of 0.08 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.18 Cr.. The value appears to be declining and may need further review. It has decreased from -0.10 Cr. (Mar 2025) to -0.18 Cr., marking a decrease of 0.08 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.08 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.07 Cr. (Mar 2025) to 0.08 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.26 Cr.. The value appears to be declining and may need further review. It has decreased from -0.17 Cr. (Mar 2025) to -0.26 Cr., marking a decrease of 0.09 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is -0.26 Cr.. The value appears to be declining and may need further review. It has decreased from -0.17 Cr. (Mar 2025) to -0.26 Cr., marking a decrease of 0.09 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.03. The value appears to be declining and may need further review. It has decreased from -0.02 (Mar 2025) to -0.03, marking a decrease of 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:17 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 213.97 | 255.89 | 137.22 | 79.32 | 173.32 | 155.48 | 0.00 | 0.00 | 0.00 | 1.67 | 0.00 | 0.00 | 0.00 |
| Expenses | 201.10 | 240.58 | 162.03 | 128.53 | 197.18 | 159.09 | 0.61 | 0.50 | 0.50 | 2.44 | 0.53 | 0.45 | 0.48 |
| Operating Profit | 12.87 | 15.31 | -24.81 | -49.21 | -23.86 | -3.61 | -0.61 | -0.50 | -0.50 | -0.77 | -0.53 | -0.45 | -0.48 |
| OPM % | 6.01% | 5.98% | -18.08% | -62.04% | -13.77% | -2.32% | -46.11% | ||||||
| Other Income | 0.30 | 1.27 | 0.96 | -16.53 | 11.87 | 2.10 | 85.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 7.57 | 9.39 | 12.74 | 11.57 | 0.19 | 4.71 | 0.01 | 0.00 | 0.00 | 0.03 | 0.15 | 0.28 | 0.32 |
| Depreciation | 4.25 | 2.37 | 2.13 | 5.34 | 6.96 | 9.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 1.35 | 4.82 | -38.72 | -82.65 | -19.14 | -15.51 | 84.47 | -0.50 | -0.50 | -0.80 | -0.68 | -0.73 | -0.80 |
| Tax % | 0.00% | 18.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 26.25% | 0.00% | 0.00% | |
| Net Profit | 1.35 | 3.93 | -38.73 | -82.65 | -19.14 | -15.51 | 84.47 | -0.50 | -0.50 | -1.01 | -0.68 | -0.73 | -0.80 |
| EPS in Rs | 0.27 | 0.77 | -6.27 | -10.49 | -2.43 | -1.97 | 10.72 | -0.06 | -0.06 | -0.13 | -0.09 | -0.09 | -0.10 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 191.11% | -1085.50% | -113.40% | 76.84% | 18.97% | 644.62% | -100.59% | 0.00% | -102.00% | 32.67% | -7.35% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1276.61% | 972.10% | 190.24% | -57.88% | 625.65% | -745.21% | 100.59% | -102.00% | 134.67% | -40.03% |
Gayatri BioOrganics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -8% |
| 3 Years: | -19% |
| TTM: | -12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 18% |
| 3 Years: | 3% |
| 1 Year: | 103% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 3:31 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 162.69 | 63.12 | 116.05 | 6.95 | 3.18 | 1.22 | 54.64 | |||||
| Inventory Days | 51.08 | 62.87 | 98.30 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Days Payable | 177.53 | 58.80 | 79.17 | |||||||||
| Cash Conversion Cycle | 36.24 | 67.19 | 135.18 | 6.95 | 3.18 | 1.22 | 54.64 | |||||
| Working Capital Days | -18.12 | 5.32 | -103.13 | -365.55 | -212.09 | -271.31 | -7,048.65 | |||||
| ROCE % | 10.65% | 14.68% | -27.28% | -209.87% | -21.01% | -26.53% | -54.61% | -44.54% | -40.72% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Large & Midcap Fund | 452,200 | 0 | 0.26 | 452,200 | 2025-04-22 15:56:50 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -72.65 | -0.09 | -0.13 | -0.06 | -0.06 |
| Diluted EPS (Rs.) | -72.65 | -0.09 | -0.13 | -0.06 | -0.06 |
| Cash EPS (Rs.) | -0.09 | -0.08 | -0.12 | -0.06 | -0.06 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -4.55 | -4.46 | -4.38 | -4.25 | -4.18 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -4.55 | -4.46 | -4.38 | -4.25 | -4.18 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 |
| PBDIT / Share (Rs.) | -0.05 | -0.06 | -0.09 | -0.06 | -0.06 |
| PBIT / Share (Rs.) | -0.05 | -0.06 | -0.09 | -0.06 | -0.06 |
| PBT / Share (Rs.) | -0.09 | -0.08 | -0.10 | -0.06 | -0.06 |
| Net Profit / Share (Rs.) | -0.09 | -0.08 | -0.12 | -0.06 | -0.06 |
| PBDIT Margin (%) | 0.00 | 0.00 | -46.06 | 0.00 | 0.00 |
| PBIT Margin (%) | 0.00 | 0.00 | -46.06 | 0.00 | 0.00 |
| PBT Margin (%) | 0.00 | 0.00 | -47.72 | 0.00 | 0.00 |
| Net Profit Margin (%) | 0.00 | 0.00 | -60.60 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 1.38 | 1.65 | 2.38 | 1.56 | 1.58 |
| Return On Assets (%) | -43.67 | -43.18 | -62.54 | -22.19 | -19.17 |
| Long Term Debt / Equity (X) | -0.09 | -0.08 | -0.06 | -0.05 | -0.05 |
| Total Debt / Equity (X) | -1.03 | -1.03 | -1.03 | -1.05 | -1.06 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.86 | 0.00 | 0.00 |
| Current Ratio (X) | 0.04 | 0.04 | 0.04 | 0.06 | 0.07 |
| Quick Ratio (X) | 0.04 | 0.04 | 0.04 | 0.06 | 0.07 |
| Interest Coverage Ratio (X) | -1.62 | -3.56 | -27.83 | -1652.67 | -496.40 |
| Interest Coverage Ratio (Post Tax) (X) | -1.62 | -3.56 | -35.61 | -1652.67 | -496.40 |
| Enterprise Value (Cr.) | 90.61 | 75.80 | 92.13 | 182.80 | 85.41 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 55.25 | 0.00 | 0.00 |
| EV / EBITDA (X) | -201.50 | -142.51 | -119.94 | -368.70 | -172.05 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 33.88 | 0.00 | 0.00 |
| Price / BV (X) | -1.50 | -1.12 | -1.64 | -4.41 | -1.54 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 33.98 | 0.00 | 0.00 |
| EarningsYield | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
After reviewing the key financial ratios for Gayatri BioOrganics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -72.65. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -72.65, marking a decrease of 72.56.
- For Diluted EPS (Rs.), as of Mar 25, the value is -72.65. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -72.65, marking a decrease of 72.56.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 3. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -4.55. It has decreased from -4.46 (Mar 24) to -4.55, marking a decrease of 0.09.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -4.55. It has decreased from -4.46 (Mar 24) to -4.55, marking a decrease of 0.09.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.05. This value is below the healthy minimum of 2. It has increased from -0.06 (Mar 24) to -0.05, marking an increase of 0.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.05. This value is below the healthy minimum of 0. It has increased from -0.06 (Mar 24) to -0.05, marking an increase of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 0. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 2. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.38. This value is below the healthy minimum of 10. It has decreased from 1.65 (Mar 24) to 1.38, marking a decrease of 0.27.
- For Return On Assets (%), as of Mar 25, the value is -43.67. This value is below the healthy minimum of 5. It has decreased from -43.18 (Mar 24) to -43.67, marking a decrease of 0.49.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 0.2. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is -1.03. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded -1.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1.62. This value is below the healthy minimum of 3. It has increased from -3.56 (Mar 24) to -1.62, marking an increase of 1.94.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1.62. This value is below the healthy minimum of 3. It has increased from -3.56 (Mar 24) to -1.62, marking an increase of 1.94.
- For Enterprise Value (Cr.), as of Mar 25, the value is 90.61. It has increased from 75.80 (Mar 24) to 90.61, marking an increase of 14.81.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -201.50. This value is below the healthy minimum of 5. It has decreased from -142.51 (Mar 24) to -201.50, marking a decrease of 58.99.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is -1.50. This value is below the healthy minimum of 1. It has decreased from -1.12 (Mar 24) to -1.50, marking a decrease of 0.38.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded -0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gayatri BioOrganics Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.38% (Industry Average ROCE: 40.7%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 0%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1.62
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.04
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 0)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -1.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Cellulose Derivatives | B3, 3rd Floor, 6-3-1090, Rajbhavan Road, Hyderabad Telangana 500082 | info@gayatribioorganics.com http://www.gayatribioorganics.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. T V Sandeep Kumar Reddy | Chairman & Non-Exe.Director |
| Mr. K Sreedhara Reddy | Whole Time Director |
| Mrs. Meenakshi Ramchand Sachdeva | Independent Director |
| Mr. P V Narayana Rao | Independent Director |
| Mr. Srinivas Iduri | Independent Director |